HR
Hardeo Ram Kaler
About Hardeo Ram Kaler
Data last updated:
Hardeo Ram Kaler has 21 years in corporate governance. Holds Director role. Currently with 3 companies, including Deevee Marbles Private Limited and Frontline Infratech Private Limited. Formerly with 1 company, such as Tenfold Pharmaceuticals Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
 Deevee Marbles Private Limited U14101RJ1994PTC008359 | Director | 01 Feb 2012 | 1994 | Active |
| Frontline Infratech Private Limited U70101RJ2011PTC033910 | Director | 20 Jan 2011 | 2011 | Active |
| Safe And Cure Superspecialities Hospital Private Limited U74999RJ2018PTC061784 | Director | 12 Jul 2018 | 2018 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Tenfold Pharmaceuticals Private Limited U24232RJ2005PTC021301 | Director | 13 Sep 2005 | 2005 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Hardeo Ram Kaler
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hardeo Ram Kaler
Hardeo Ram Kaler has 21 years in corporate governance. Holds Director role. Currently with 3 companies, including Deevee Marbles Private Limited and Frontline Infratech Private Limited. Formerly with 1 company, such as Tenfold Pharmaceuticals Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Hardeo Ram Kaler is associated with 3 companies as Director.
Hardeo Ram Kaler has expertise in General Business, Technology.
Hardeo Ram Kaler has 21 years in corporate governance.